Using the CHADS2 and CHA2DS2-VASc scores for stroke risk prediction as well as the identification of stroke outcomes and cardiac complications in patients with and without atrial fibrillation

Cerebrovascular Diseases

Volumn 36, Issue 4, 2013, Pages 281-282

  Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; WARFARIN; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHA2DS2 SCORE; CHADS2 SCORE; COMORBIDITY; HEART ATRIUM FIBRILLATION; NOTE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; ATRIAL FIBRILLATION; CARDIAC PATIENT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; HUMAN; HYPERTENSION; MORTALITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; RANKIN SCALE; RISK ASSESSMENT; SCORING SYSTEM; DECISION SUPPORT SYSTEM; FEMALE; MALE;

ATRIAL FIBRILLATION; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MALE; STROKE;

EID: 84885494713     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000355981     Document Type: Note

References (20)

1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263-272.
2. Friberg L, Rosenqvist M, Lip GY: Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33: 1500-1510.
3. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY: The value of the CHA 2 DS 2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS 2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107: 1172-1179.
4. Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Prostran MS, Lip GY: Reliable identification of 'truly low' thromboembolic risk in patients initially diagnosed with 'lone' atrial fibrillation: the Belgrade Atrial Fibrillation Study. Circ Arrhythm Electrophysiol 2012; 5: 319-326.
5. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C: Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
6. Camm AJ, Lip GY, de Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines-CPG, Document Reviewers: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-1413.
7. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, Maywald U, Kohlmann T, Feng YS, Breithardt G, Bauersachs R: Oral anticoagulation use by patients with atrial fibrillation in Germany: adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065.
8. Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A, Wegscheider K, Treszl A, Meinertz T, Oeff M, Ravens U, Breithardt G, Steinbeck G, AFNET Registry Investigators: Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost 2011; 105: 1010-1023.
9. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP: Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
10. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A: Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
11. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY: Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
12. Lip GY: Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why Eur Heart J 2013; 34: 1041-1049.
13. Hippisley-Cox J, Coupland C, Brindle P: Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ 2013; 346:f2573.
14. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, Reynolds K, Go AS: A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013; 2:e000250.
15. Ntaios G, Lip GY, Makaritsis K, Papavasileiou V, Vemmou A, Koroboki E, Savvari P, Manios E, Milionis H, Vemmos K: CHADS 2 , CHA 2 DS 2-VASc, and long-term stroke outcome in patients without atrial fibrillation. Neurology 2013; 80: 1009-1017.
16. Lip GY, Lin HJ, Chien KL, Hsu HC, Su TC, Chen MF, Lee YT: Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. Int J Cardiol 2013; 168: 414-419.
17. Poçi D, Hartford M, Karlsson T, Herlitz J, Edvardsson N, Caidahl K: Role of the CHADS 2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest 2012; 141: 1431-1440.
18. Tu HTH, Campbell BCV, Meretoja A, Churilov L, Lees KR, Donnan GA, Davis SM, VISTA collaborators: Pre-stroke CHADS 2 and CHA 2 DS 2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation. Cerebrovasc Dis 2013; 36:273-280.
19. Apostolakis S, Sullivan RM, Olshansky B, Lip GY: Factors affecting quality of anticoagulation control amongst atrial fibrillation patients on warfarin: the SAMe-TT 2 R 2 (Sex female, Age less than 60, Medical history, Treatment strategy [rhythm control], Tobacco use [doubled], Race [doubled]) score. Chest 2013, E-pub ahead of print.
20. Eckman MH, Singer DE, Rosand J, Greenberg SM: Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011; 4: 14-21.